Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2020 by Manufacturers, Type and Application, Forecast to 2025

  • receipt Report ID : 103882
  • calendar_today Published On: Sep, 2020
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

Market Overview

The Benign Prostatic Hyperplasia (BPH) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Benign Prostatic Hyperplasia (BPH) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 0.9%% in the forecast period of 2020 to 2025 and will expected to reach USD 3540.4 million by 2025, from USD 3417.1 million in 2019.

Market segmentation

Benign Prostatic Hyperplasia (BPH) Drugs market is split by Type and Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Breakdown by Type, Benign Prostatic Hyperplasia (BPH) Drugs market has been segmented into Alpha-Blocker, Phosphodiesterase Type-5 Inhibitors, Others, etc.

Breakdown by Application, Benign Prostatic Hyperplasia (BPH) Drugs has been segmented into Hospitals, Drugstores, Others, etc.

Regions and Countries Level Analysis

Regional analysis is another highly comprehensive part of the research and analysis study of the global Benign Prostatic Hyperplasia (BPH) Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Benign Prostatic Hyperplasia (BPH) Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Benign Prostatic Hyperplasia (BPH) Drugs market.

For Japan, this report analyses the Japan market by players, Type and Application, for the period 2015-2025.

Competitive Landscape and Benign Prostatic Hyperplasia (BPH) Drugs Market Share Analysis

Benign Prostatic Hyperplasia (BPH) Drugs competitive landscape provides details by vendors, including company overview, company total revenue, market potential, global presence, Benign Prostatic Hyperplasia (BPH) Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Benign Prostatic Hyperplasia (BPH) Drugs sales, revenue and market share for each player covered in this report.

The major players covered in Benign Prostatic Hyperplasia (BPH) Drugs are: Eli Lilly, TEVA, Sanofi, GlaxoSmithKline, Allergan, Astellas Pharma, Novartis, Abbott, Pfizer, Mylan, Merck, etc. Among other players domestic and global, Benign Prostatic Hyperplasia (BPH) Drugs market share data is available for global, North America, Europe, Asia, Middle East and Africa and South America separately. Our analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The key market players for global Benign Prostatic Hyperplasia (BPH) Drugs market are listed below:

Eli Lilly

TEVA

Sanofi

GlaxoSmithKline

Allergan

Astellas Pharma

Novartis

Abbott

Pfizer

Mylan

Merck

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)

South America (Brazil, Argentina)

Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Market segment by Type, covers:

Alpha-Blocker

Phosphodiesterase Type-5 Inhibitors

Others

Market segment by Application, can be divided into

Hospitals

Drugstores

Others

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Benign Prostatic Hyperplasia (BPH) Drugs Introduction

1.2 Market Analysis by Type

1.2.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type: 2015 VS 2019 VS 2025

1.2.2 Alpha-Blocker

1.2.3 Phosphodiesterase Type-5 Inhibitors

1.2.4 Others

1.3 Market Analysis by Application

1.3.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application: 2015 VS 2019 VS 2025

1.3.2 Hospitals

1.3.3 Drugstores

1.3.4 Others

1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Forecast (2015-2025)

1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Forecast (2015-2025)

1.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Overview by Geography (2015-2020)

2 Manufacturers Profiles

2.1 Eli Lilly

2.1.1 Eli Lilly Details

2.1.2 Eli Lilly Major Business

2.1.3 Eli Lilly SWOT Analysis

2.1.4 Eli Lilly Product and Services

2.1.5 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

2.2 TEVA

2.2.1 TEVA Details

2.2.2 TEVA Major Business

2.2.3 TEVA SWOT Analysis

2.2.4 TEVA Product and Services

2.2.5 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

2.3 Sanofi

2.3.1 Sanofi Details

2.3.2 Sanofi Major Business

2.3.3 Sanofi SWOT Analysis

2.3.4 Sanofi Product and Services

2.3.5 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

2.4 GlaxoSmithKline

2.4.1 GlaxoSmithKline Details

2.4.2 GlaxoSmithKline Major Business

2.4.3 GlaxoSmithKline SWOT Analysis

2.4.4 GlaxoSmithKline Product and Services

2.4.5 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

2.5 Allergan

2.5.1 Allergan Details

2.5.2 Allergan Major Business

2.5.3 Allergan SWOT Analysis

2.5.4 Allergan Product and Services

2.5.5 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

2.6 Astellas Pharma

2.6.1 Astellas Pharma Details

2.6.2 Astellas Pharma Major Business

2.6.3 Astellas Pharma Product and Services

2.6.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

2.7 Novartis

2.7.1 Novartis Details

2.7.2 Novartis Major Business

2.7.3 Novartis Product and Services

2.7.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

2.8 Abbott

2.8.1 Abbott Details

2.8.2 Abbott Major Business

2.8.3 Abbott Product and Services

2.8.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

2.9 Pfizer

2.9.1 Pfizer Details

2.9.2 Pfizer Major Business

2.9.3 Pfizer Product and Services

2.9.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

2.10 Mylan

2.10.1 Mylan Details

2.10.2 Mylan Major Business

2.10.3 Mylan Product and Services

2.10.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

2.11 Merck

2.11.1 Merck Details

2.11.2 Merck Major Business

2.11.3 Merck Product and Services

2.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market, Company Landscape

3.1 Company Market Share Analysis: Global

3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Manufacturer (2018-2019)

3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Manufacturer (2018-2019)

3.2 Company Market Share Analysis: Japan

3.2.1 Key Players Benign Prostatic Hyperplasia (BPH) Drugs Sales in Japan (2018-2019)

3.2.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer (2018-2019)

3.3 Market Concentration Rate

3.3.1 Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2019

3.3.2 Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2019

4 Market Size by Geography

4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Geography (2015-2020)

4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geography (2015-2020)

4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions (2015-2020)

4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Regions (2020-2025)

4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Forecast by Regions (2020-2025)

4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Forecast by Regions (2020-2025)

4.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

4.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

4.5 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

4.6 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

4.7 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

5 North America by Country

5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2015-2020)

5.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Country (2015-2020)

5.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Country (2015-2020)

5.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Country (2020-2025)

5.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Forecast by Country (2020-2025)

5.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Forecast by Country (2020-2025)

5.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

5.4 Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

5.5 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

6 Europe by Country

6.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2015-2020)

6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020)

6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020)

6.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Country (2020-2025)

6.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Forecast by Country (2020-2025)

6.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Forecast by Country (2020-2025)

6.3 Germany Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

6.4 United Kingdom Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

6.5 France Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

6.6 Russia Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

6.7 Italy Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

7 Asia-Pacific by Regions

7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (2015-2020)

7.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2015-2020)

7.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2015-2020)

7.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Region (2020-2025)

7.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Forecast by Region (2020-2025)

7.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Forecast by Region (2020-2025)

7.3 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

7.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

7.5 Korea Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

7.6 India Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

7.7 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

7.8 Australia Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

8 South America by Country

8.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2015-2020)

8.1.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020)

8.1.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020)

8.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Country (2020-2025)

8.2.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Forecast by Country (2020-2025)

8.2.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Forecast by Country (2020-2025)

8.3 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

8.4 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

9 Middle East & Africa by Countries

9.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2015-2020)

9.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020)

9.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020)

9.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Country (2020-2025)

9.2.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Forecast by Country (2020-2025)

9.2.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Forecast by Country (2020-2025)

9.3 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

9.4 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

9.5 Egypt Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

9.6 South Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast (2015-2025)

10 Market Segment by Type

10.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2020)

10.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2015-2020)

10.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2015-2020)

10.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2015-2020)

10.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Type (2020-2025)

10.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Forecast by Type (2020-2025)

10.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Forecast by Type (2020-2025)

10.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price and Forecast by Type (2020-2025)

10.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Type (2015-2025)

10.3.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2020)

10.3.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Type (2020-2025)

11 Market Segment by Application

11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2015-2020)

11.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2015-2020)

11.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2015-2020)

11.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2015-2020)

11.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Application (2020-2025)

11.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Forecast by Application (2020-2025)

11.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Forecast by Application (2020-2025)

11.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price and Forecast by Application (2020-2025)

11.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Application (2015-2025)

11.3.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2015-2020)

11.3.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Application (2020-2025)

12 Sales Channel, Distributors, Costumers, and Market Dynamics

12.1 Sales Channel

12.1.1 Direct Marketing

12.1.2 Indirect Marketing

12.2 Distributors, Traders and Dealers

12.4.1 Market Opportunities

12.4.2 Market Risk

12.4.3 Market Driving Force

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

14.3 Disclaimer

14.4 About US

List of Tables

Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025

Table 2. Breakdown of Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)

Table 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025

Table 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Overview by Geography (2015-2020) (USD Million)

Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Estimation in Various Scenarios in 2020

Table 6. Eli Lilly Basic Information, Manufacturing Base and Competitors

Table 7. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Major Business

Table 8. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)

Table 9. Eli Lilly SWOT Analysis

Table 10. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product and Services

Table 11. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue, Gross Margin and Market Share (2018-2019)

Table 12. TEVA Basic Information, Manufacturing Base and Competitors

Table 13. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Major Business

Table 14. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)

Table 15. TEVA SWOT Analysis

Table 16. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product and Services

Table 17. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue, Gross Margin and Market Share (2018-2019)

Table 18. Sanofi Basic Information, Manufacturing Base and Competitors

Table 19. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Major Business

Table 20. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)

Table 21. Sanofi SWOT Analysis

Table 22. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product and Services

Table 23. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue, Gross Margin and Market Share (2018-2019)

Table 24. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors

Table 25. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Major Business

Table 26. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)

Table 27. GlaxoSmithKline SWOT Analysis

Table 28. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product and Services

Table 29. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue, Gross Margin and Market Share (2018-2019)

Table 30. Allergan Basic Information, Manufacturing Base and Competitors

Table 31. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Major Business

Table 32. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)

Table 33. Allergan SWOT Analysis

Table 34. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services

Table 35. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue, Gross Margin and Market Share (2018-2019)

Table 36. Astellas Pharma Basic Information, Manufacturing Base and Competitors

Table 37. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Major Business

Table 38. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)

Table 39. Astellas Pharma SWOT Analysis

Table 40. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product and Services

Table 41. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue, Gross Margin and Market Share (2018-2019)

Table 42. Novartis Basic Information, Manufacturing Base and Competitors

Table 43. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Major Business

Table 44. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)

Table 45. Novartis SWOT Analysis

Table 46. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product and Services

Table 47. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue, Gross Margin and Market Share (2018-2019)

Table 48. Abbott Basic Information, Manufacturing Base and Competitors

Table 49. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Major Business

Table 50. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)

Table 51. Abbott SWOT Analysis

Table 52. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product and Services

Table 53. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue, Gross Margin and Market Share (2018-2019)

Table 54. Pfizer Basic Information, Manufacturing Base and Competitors

Table 55. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Major Business

Table 56. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)

Table 57. Pfizer SWOT Analysis

Table 58. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product and Services

Table 59. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue, Gross Margin and Market Share (2018-2019)

Table 60. Mylan Basic Information, Manufacturing Base and Competitors

Table 61. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Major Business

Table 62. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)

Table 63. Mylan SWOT Analysis

Table 64. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services

Table 65. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue, Gross Margin and Market Share (2018-2019)

Table 66. Merck Basic Information, Manufacturing Base and Competitors

Table 67. Merck Benign Prostatic Hyperplasia (BPH) Drugs Major Business

Table 68. Merck Benign Prostatic Hyperplasia (BPH) Drugs Total Revenue (USD Million) (2018-2019)

Table 69. Merck SWOT Analysis

Table 70. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product and Services

Table 71. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue, Gross Margin and Market Share (2018-2019)

Table 72. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2018-2019) (M Units)

Table 73. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2018-2019) (USD Million)

Table 74. Key Players Benign Prostatic Hyperplasia (BPH) Drugs Sales in Japan (2018-2019) (M Units)

Table 75. Key Players Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Japan (2018-2019)

Table 76. Key Players Revenue of Benign Prostatic Hyperplasia (BPH) Drugs in Japan (2018-2019) (USD Million)

Table 77. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions (2015-2020) (M Units)

Table 78. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions (2015-2020)

Table 79. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions (2015-2020) (USD Million)

Table 80. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Forecast by Regions (2020-2025) (M Units)

Table 81. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions (2020-2025)

Table 82. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Forecast by Regions (2020-2025) (USD Million)

Table 83. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions (2020-2025) (USD Million)

Table 84. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2015-2020) (M Units)

Table 85. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2015-2020)

Table 86. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2015-2020) (USD Million)

Table 87. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2015-2020)

Table 88. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) (M Units)

Table 89. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2020-2025)

Table 90. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) (USD Million)

Table 91. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2025)

Table 92. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2015-2020) (M Units)

Table 93. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2015-2020)

Table 94. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2015-2020) (USD Million)

Table 95. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2015-2020)

Table 96. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) (M Units)

Table 97. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2020-2025)

Table 98. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) (USD Million)

Table 99. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2025)

Table 100. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2015-2020) (M Units)

Table 101. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2015-2020)

Table 102. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2015-2020) (USD Million)

Table 103. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2015-2020)

Table 104. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) (M Units)

Table 105. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2020-2025)

Table 106. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) (USD Million)

Table 107. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2025)

Table 108. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2015-2020) (M Units)

Table 109. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2015-2020)

Table 110. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2015-2020) (USD Million)

Table 111. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2015-2020)

Table 112. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) (M Units)

Table 113. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2020-2025)

Table 114. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) (USD Million)

Table 115. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2025)

Table 116. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2015-2020) (M Units)

Table 117. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2015-2020)

Table 118. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2015-2020) (USD Million)

Table 119. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2015-2020)

Table 120. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2025) (M Units)

Table 121. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2020-2025)

Table 122. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2020-2025) (USD Million)

Table 123. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2020-2025)

Table 124. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2015-2020) (M Units)

Table 125. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)

Table 126. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2015-2020) (USD Million)

Table 127. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2015-2020)

Table 128. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) (M Units)

Table 129. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)

Table 130. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2020-2025) (USD Million)

Table 131. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2020-2025)

Table 132. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2015-2020) (M Units)

Table 133. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)

Table 134. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2015-2020) (USD Million)

Table 135. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2015-2020)

Table 136. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2015-2020) (US$/Unit)

Table 137. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) (M Units)

Table 138. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)

Table 139. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2020-2025) (USD Million)

Table 140. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2020-2025)

Table 141. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2020-2025) (US$/Unit)

Table 142. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2015-2020) (M Units)

Table 143. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)

Table 144. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2015-2020) (USD Million)

Table 145. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2015-2020)

Table 146. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) (M Units)

Table 147. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)

Table 148. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2020-2025) (USD Million)

Table 149. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2020-2025)

Table 150. Direct Channel Pros & Cons

Table 151. Indirect Channel Pros & Cons

Table 152. Distributors/Traders/ Dealers List

Table 153. Customers of Benign Prostatic Hyperplasia (BPH) Drugs

Table 154. Market Opportunities in Next Few Years

Table 155. Market Risks Analysis

Table 156. Market Drivers

List of Figures

Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Picture

Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 3. Alpha-Blocker Picture

Figure 4. Phosphodiesterase Type-5 Inhibitors Picture

Figure 5. Others Picture

Figure 6. Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2019

Figure 7. Hospitals Picture

Figure 8. Drugstores Picture

Figure 9. Others Picture

Figure 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Outlook (2015-2025) (USD Million)

Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2025) (M Units)

Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2019

Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2019

Figure 14. Key Players Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in Japan in 2019

Figure 15. Global Top 5 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2019

Figure 16. Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share in Japan in 2019

Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2019

Figure 18. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2025) (M Units)

Figure 19. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY Growth (2015-2025) (USD Million)

Figure 20. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2020) (M Units)

Figure 21. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY Growth (2015-2020) (USD Million)

Figure 22. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2020) (M Units)

Figure 23. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY Growth (2015-2020) (USD Million)

Figure 24. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2020) (M Units)

Figure 25. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY Growth (2015-2020) (USD Million)

Figure 26. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY Growth (2015-2020) (M Units)

Figure 27. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY Growth (2015-2020) (USD Million)

Figure 28. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2019

Figure 29. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2019

Figure 30. United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate (2015-2025) (USD Million)

Figure 31. Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate (2015-2025) (USD Million)

Figure 32. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate (2015-2020) (USD Million)

Figure 33. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2019

Figure 34. Germany Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 35. United Kingdom Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 36. France Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 37. Russia Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 38. Italy Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 39. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region 2018

Figure 40. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region 2018

Figure 41. China Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 42. Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 43. Korea Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 44. India Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 45. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 46. Australia Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 47. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2019

Figure 48. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2019

Figure 49. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 50. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 51. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 52. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 53. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 54. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (2015-2025) (USD Million)

Figure 55. Global Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type in 2019

Figure 56. Global Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2019

Figure 57. Sales Channel: Direct Channel vs Indirect Channel

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz